Proven track record selling to commercial biotech and pharmaceutical companies, academic and non-profit research institutions, and/or government laboratories….
From Indeed – 18 Aug 2015 14:16:44 GMT
– View all San Diego jobs
Last week, 100,000 Americans with sickle cell disease and millions more around the world got encouraging news. Investors gave a vote of confidence, in the form of a $120 million IPO, to Global Blood…
[[Click headline to continue reading.]]
New Technology is Literally and Figuratively Hot Stanford-incubated Startup has Patent for Semiconductor-based Sequencing Using Proton or Heat Detection Sizzling Hot Promises Draw Stellar Scientific Advisor Board and World Renown Venture Capitalists Truth be told, I’ve been an avid follower—if… More…
Epic Sciences’ Dr. Dena Marrinucci Is Recognized as an Honoree of MIT Technology Review’s Annual INNOVATORS UNDER 35 List
SAN DIEGO, Aug. 18, 2015 /PRNewswire/ — Today, MIT Technology Review revealed its annual list of Innovators Under 35. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world. For her work in the field of biotechnology and medicine, Epic Sciences’ Dena Marrinucci, Ph.D., has been recognized as an entrepreneur on the list for her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments.
The deadliest cancers consist of multiple cell types driven by different mutations. During the course of treatment and the disease, rare cells gain new mutations that confer resistance to a therapy. Undetected, these cells grow and evolve, resulting in metastatic cancers that are heterogeneous and difficult to treat. Dr. Marrinucci helped develop a new, unbiased, rare cell detection and analysis technology to address this urgent need.
By identifying and characterizing all types of circulating tumor cells (CTCs) in a blood sample, the no cell left behind® technology is designed to give real-time insight into how heterogeneous a patient’s cancer is and how it is responding to treatment. In addition, this technology is being developed to include single cell analysis of genetic and proteomic aberrations to guide tailored and timely treatments, including combination therapies.
“We can not wait for cancer metastases to show on PET scans and imaging technologies to know when a therapy is not working,” said Dr. Marrinucci, chief scientific officer of Epic Sciences. “CTC based testing holds the promise of delivering real-time therapeutic monitoring, whereas historical approaches do not have the needed sensitivity and reproducibility. We developed our novel technology because, to fight this disease, we need an accurate picture at any point in time of all the types of deadly cancer cells, down to the rarest ones that make up a patient’s specific cancer; because you can’t hit what you can’t see.”
Dr. Marrinucci co-founded Epic Sciences in 2008 to commercialize the technology. Today Epic Sciences has partnered with a number of pharmaceutical companies who have integrated the technology in conjunction with 50 different active clinical trials of drugs for specific cancers. Epic Sciences also works with top oncologists and cancer research centers around the world to bring the most advanced liquid biopsy technology to patients.
“Over the years, we’ve had success in choosing young innovators whose work has been profoundly influential on the direction of human affairs,” said editor in chief and publisher Jason Pontin. “Previous winners include Larry Page and Sergey Brin, the cofounders of Google; Mark Zuckerberg, the cofounder of Facebook; and Jonathan Ive, the chief designer of Apple. We’re proud of our selections and the variety of achievements they celebrate, and we’re proud to add Dr. Dena Marrinucci to this prestigious list.”
This year’s honorees will be featured online at www.technologyreview.com starting today, and in the September/October print magazine, which hits newsstands worldwide on September 1. They will appear in person at the upcoming EmTech MIT conference November 2–4 in Cambridge, Massachusetts (www.EmTechMIT.com).
About MIT Technology Review
MIT Technology Review, which is wholly owned by MIT, creates award-winning technology-related editorial content on a variety of platforms for an audience of millions of business leaders, innovators, and thought leaders, in six languages and in 147 countries. At www.technologyreview.com, readers access daily news and analysis, and the award-winning MIT Technology Review magazine has set the standard for technology publications since 1899. In addition to producing engaging live events, the company manages the global entrepreneurial organization MIT Enterprise Forum.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences’ no cell left behind™ technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences’ goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
SOURCE Epic Sciences, Inc.
Another week, another startup biotech that has amassed the type of investor group that can support an initial public offering. This time, it’s Boston-based WaVe Life Sciences. WaVe, a startup trying…
[[Click headline to continue reading.]]
EC 1069/2009, EC 142/2011) Knowledge of Dangerous Goods Transportation regulations, including IATA, DOT, ADR Familiarity with the Cartagena Protocol on…
From Becton Dickinson – 18 Aug 2015 13:46:10 GMT
– View all San Diego jobs
LAKE FOREST, Calif., Aug. 18, 2015 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution is supporting the worldwide distribution of Stemedica’s ischemic-tolerant stem cell product lines.
Stemedica Cell Technologies, Inc. (“Stemedica”) develops and manufactures best-in-class ischemic-tolerant stem cell products and biological products. Stemedica’s line of stem cell products support preclinical and clinical studies conducted by clinical research institutions and accredited hospitals. Its mesenchymal stem cells (“MSCs”), derived from adult bone marrow, and allogeneic neural stem cells (“NSCs”), taken from donated brain tissue, have received multiple Investigational New Drug (“IND”) designations and are FDA-approved for clinical trials involving the treatment of stroke, chronic heart failure, cutaneous photoaging and Alzheimer’s disease.
Cryoport’s global logistics network will provide comprehensive cryogenic logistics support for Stemedica in the distribution of their stem cell products. The Company’s validated cold chain solutions will maintain the integrity of Stemedica’s line of products and ensure reliability of delivery to Stemedica’s wide client base within the research community on a worldwide basis.
Dr. Roger J. Howe, Executive Chairman of Stemedica, commented, “Cryoport plays a critical role in providing the appropriate logistics channels for our cell therapy products. We equip the research and medical community with our cutting-edge technology to help them further their preclinical as well as clinical development activities. As such, we rely on Cryoport’s validated cryogenic logistics solutions to provide our clients uncompromised access to our allogeneic stem cell products. We believe our technology will help change and advance medicine and improve quality of life globally. The unique and important opportunities for Stemedica are being enhanced significantly by Cryoport’s cryogenic logistics solutions.”
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, “We are honored to support Stemedica in their efforts to further clinical research developments that could improve the lives of so many globally. Working with Stemedica to help advance their product portfolio will provide regenerative therapy companies access to critical manufacturing capacity and progressive cell line products. As a provider to the life sciences industry, Cryoport’s solutions are an essential element to the advancements in the industry.”
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and stem cell factors. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for chronic heart failure, cutaneous photoaging, ischemic stroke and Alzheimer’s disease. Stemedica’s products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California and can be found online at www.stemedica.com.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide with over 40 clinical trials currently being supported by Cryoport, the majority in the regenerative therapy. In addition, Cryoport actively supports the rest of the industry including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport’s investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company’s cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.
CARLSBAD, CA–(Marketwired – August 18, 2015) – International Stem Cell Corporation ( OTCQB : ISCOD ) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and bio…
Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From Ajinomoto Althea, Inc. – 18 Aug 2015 11:27:08 GMT
– View all San…
SAN DIEGO, CA–(Marketwired – August 18, 2015) – NuVasive, Inc. ( NASDAQ : NUVA ), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that Johnson Lai has…